Erastin

Catalog No.S7242

For research use only.

Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions of Erastin are best fresh-prepared.

Erastin Chemical Structure

CAS No. 571203-78-6

Selleck's Erastin has been cited by 207 publications

Purity & Quality Control

Choose Selective Ferroptosis Inhibitors

Biological Activity

Description Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions of Erastin are best fresh-prepared.
Targets
Ferroptosis [1]
In vitro

Erastin is selectively lethal to oncogenic RAS-mutant cell lines, and triggers a unique iron-dependent form of non-apoptotic cell death called ferroptosis. [1] [2] Erastin binds directly to VDAC2 and causes mitochondrial damage via ROS production in an NADH-dependent manner, which induces cell death in some tumor cells harbouring activating mutations in the RAS-RAF-MEK pathway. [3] In addition, erastin, via inducing ROS-mediated CID (Caspase-independent cell death), strongly enhances the effect of cisplatin in WT EGFR cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human BJeH cells NXPSXGZwTnWwY4Tpc44h[XO|YYm= NHr1Oow3KGh? NF;RbmFKdmS3Y4Tpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZMheHKxZIXjeIlwdiCrbjDoeY1idiCESnXIJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJHJCWyCjZoTldkA3KGi{czDifUBFS0ZvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nz MnS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNlEoRjJ{OEOyN|IyRC:jPh?=
human BJeLR cells M4fsUGN6fG:2b4jpZ:Kh[XO|YYm= MnPvNVAh|ryP M1fPTlEzKGh? MoTzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmpmVFJiY3XscJMh\XiycnXzd4lv\yCUQWOgS|EzXiCvdYThcpQh[XRiMUCgeW0h[XRiMUKgbJJ{KGK7IITyfZBidiCkbIXlJJN1[WmwaX7n NEPPTWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizNlMzOSd-MkK4N|I{OjF:L3G+
human BJ cells M3r2W2Z2dmO2aX;uJIF{e2G7 NVO4eGJ4PC54IN88US=> NUfaOG5GUW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBwgGmmYYTpeoUhe3CnY3nld{BqdiCqdX3hckBDUiClZXzsd{BmgHC{ZYPzbY5oKFSHUmSsJGxVNCCVVDDhcoQhWkGVIFexNnYhdXW2YX70JIdmdmW|IHPlcIx{KGG2IESuOkB2VQ>? M3z2Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human BJ cells NFH6UlhHfW6ldHnvckBie3OjeR?= MWi5JO69VQ>? MVPJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCESjDj[YxteyCneIDy[ZN{cW6pIGTFVnQtKEyWLDDTWEBidmRiUlHTJGcyOlZibYX0ZY51KGenbnXzJINmdGy|IHH0JFkhfU1w M1XsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human BJ cells NI\oendHfW6ldHnvckBie3OjeR?= NV3MWZd7UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyCrbjDwdoV{\W6lZTDv[kBWODF{NjDifUB1enmyYX6gZox2\SCneHPseZNqd25ibXX0bI9lNCCLQ{WwQVMyNjJizszNMi=> NF3NSY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human A673 cells MlfjSpVv[3Srb36gZZN{[Xl? NX7XdmVDUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRVY4OyClZXzsd{whTUN3ME2zNEDPxE1w MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human MX2 cells NIG5RY9HfW6ldHnvckBie3OjeR?= NYHVeoVbUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gUXgzKGOnbHzzMEBGSzVyPUG4JO69VS5? NWPoe|lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human HOS cells M1LjS2Z2dmO2aX;uJIF{e2G7 NYr1d4dnUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTG9UKGOnbHzzJEwhTUN3ME2xO{DPxE1w NXHOR5d1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human Hs925.T cells M{jSbGZ2dmO2aX;uJIF{e2G7 NWf1U2dHUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTJM6OjVwVDDj[YxteyxiRVO1NF0yPyEQvF2u MmfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human Hs51.T cells NGPqNZJHfW6ldHnvckBie3OjeR?= MWnJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCKc{WxMnQh[2WubIOsJGVEPTB;MUKg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human EWS502 cells MnHZSpVv[3Srb36gZZN{[Xl? MlL1TY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iRWfTOVAzKGOnbHzzMEBGSzVyPUGwJO69VS5? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human BJ cells MWDGeY5kfGmxbjDhd5NigQ>? MlPZTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gWGVTXCCneIDy[ZN{cW6pIHj1cYFvKEKMIHPlcIx{NCCHQ{WwQVExKM7:TT6= M4f1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human TC71 cells NH7mWppHfW6ldHnvckBie3OjeR?= NVv5OmFvUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gWGM4OSClZXzsd{whTUN3ME2xNEDPxE1w NHq4WWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human U937 cells NH;ObXRHfW6ldHnvckBie3OjeR?= NXHGPVNvUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gWVk{PyClZXzsd{whTUN3ME2xNEDPxE1w NInnS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human SK-N-MC cells NFLyPXNHfW6ldHnvckBie3OjeR?= MV\JcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVSz3OMW1EKGOnbHzzMEBGSzVyPUGwJO69VS5? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human TC32 cells NELEVXFHfW6ldHnvckBie3OjeR?= MYPJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCWQ{OyJINmdGy| NH2zPVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human U2OS cells MlPNSpVv[3Srb36gZZN{[Xl? MV7JcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCXMl;TJINmdGy|LDDFR|UxRTZizszNMi=> MoiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human LNCaP cells NVHUbJY3TnWwY4Tpc44h[XO|YYm= M3PNSmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFzOR4FRKGOnbHzzMEBGSzVyPU[g{txONg>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human Calu1 cells M3fnRmZ2dmO2aX;uJIF{e2G7 MkO0TY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3MTDj[YxteyCneIDy[ZN{cW6pIFvSRXMhf2m2aDDhZ5RqfmG2aX7nJI12fGG2aX;ud{BjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:PCEQvF2u NUmzNoRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human SKUT cells M2XNZ2Z2dmO2aX;uJIF{e2G7 MXrJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCVS2XUJINmdGy|LDDFR|UxRTRizszNMi=> NI\KWmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human MES-SA cells MWnGeY5kfGmxbjDhd5NigQ>? MnL1TY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTVXTMXNCKGOnbHzzMEBGSzVyPUOg{txONg>? NYrTXINKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human SVR cells NYXrWVdzTnWwY4Tpc44h[XO|YYm= MoXaTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iU2\SJINmdGy|LDDFR|UxRTJwNTFOwG0v M3H3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human HT1080 cells Ml3PSpVv[3Srb36gZZN{[Xl? NWGzNpNYUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTHQyODhyIHPlcIx{KGmwIIDy[ZNmdmOnIH;mJHBFNTl6MEW5JIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDt[ZRpd2RuIFnDOVA:OSEQvF2u NX7hTZN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human BJ cells M1HoVmZ2dmO2aX;uJIF{e2G7 NUH4VpVsUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyClZXzsd{BqdiCycnXz[Y5k\SCxZjDQSE06QDB3OTDifUB1enmyYX6gZox2\SCneHPseZNqd25ibXX0bI9lNCCLQ{WwQVAvQSEQvF2u Mnf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human HeLa cells MlrTSpVv[3Srb36gZZN{[Xl? MUHJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCKZVzhJINmdGy|LDDFR|UxRTBwNjFOwG0v M1[wOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human CCF-STTG1 cells MXLGeY5kfGmxbjDhd5NigQ>? NEnKRVZKdmirYnn0bY9vKG:oIGjjeEBqdiCqdX3hckBES0ZvU2TUS|Eh[2WubIOgZZN{\XO|ZXSgZZMh\2y3dHHtZZRmKHKnbHXhd4Uh[W[2ZYKgNkBpenNiYomg[ox2d3KxbXX0dpktKEmFNUC9NE4zKM7:TT6= NFLP[oE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE2Pid-Mk[yN|EyPTZ:L3G+
Assay
Methods Test Index PMID
Western blot HSPA5 / p-EIF2AK3 ; TfR1 / p-JNK / JNK / p-P38 ; GPX4 / cleaved-PARP / cleaved-caspase3 / LC3 / p62 / LDH / HMGB1 ; GRP78 28130223 31105999 27308510 29383150
Growth inhibition assay Cell survival 29348676
Immunofluorescence HMGB1 31105999

Protocol (from reference)

Cell Research:[1]
  • Cell lines: BJ-TERT/LT/ST/RASV12 cells
  • Concentrations: 5 or 10 μg/mL
  • Incubation Time: 6-11 hours
  • Method: BJ-TERT/LT/ST/RASV12 cells are seeded in 100 mm dishes and allowed to grow overnight. Cells are treated with erastin (5 or 10 μg/ml) for 6, 8, or 11 hr. A camptothecin-treated (0.4 μg/ml) control is maintained, treated at the time of seeding for 20 hours. After the treatment, cells are harvested with trypsin/EDTA and washed once with fresh medium containing serum and then twice with phosphate-buffered saline. Cells are resuspended in 1× binding buffer. 100 μL is incubated with 5 μL of Annexin V-FITC and propidium iodiode for 15 min in the dark at room temperature. Then 400 μl of the 1× binding buffer s added and the cells analyzed by flow cytometry. Data are acquired and analyzed using Cellquest software. Only viable cells that do not stain with propidium iodiode are analzyed for Annexin V-FITC staining using the FL1 channel.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.

1.25mg/mL

Chemical Information

Molecular Weight 547.04
Formula

C30H31ClN4O4

CAS No. 571203-78-6
Storage 3 years -20°C powder
Smiles CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Erastin | Erastin supplier | purchase Erastin | Erastin cost | Erastin manufacturer | order Erastin | Erastin distributor